Sana Biotechnology (NASDAQ:SANA) Trading Up 7.4% Following Analyst Upgrade

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price was up 7.4% on Tuesday after Bank of America raised their price target on the stock from $6.00 to $7.00. Bank of America currently has a buy rating on the stock. Sana Biotechnology traded as high as $4.46 and last traded at $4.3620. Approximately 634,615 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 1,475,205 shares. The stock had previously closed at $4.06.

A number of other equities analysts also recently weighed in on SANA. HC Wainwright cut their target price on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Monday, December 29th. Citigroup restated an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Wall Street Zen upgraded shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Citizens Jmp boosted their target price on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Sana Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $8.14.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC boosted its holdings in shares of Sana Biotechnology by 673.8% in the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock worth $30,000 after acquiring an additional 9,501 shares during the period. Hoey Investments Inc. purchased a new stake in shares of Sana Biotechnology in the second quarter worth about $33,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Sana Biotechnology in the third quarter valued at approximately $36,000. TD Waterhouse Canada Inc. purchased a new position in Sana Biotechnology during the third quarter valued at approximately $37,000. Finally, Lyell Wealth Management LP purchased a new stake in Sana Biotechnology in the 3rd quarter worth approximately $37,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

The company’s 50 day simple moving average is $4.32 and its 200-day simple moving average is $3.98. The firm has a market capitalization of $1.14 billion, a PE ratio of -4.42 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. On average, equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.